Sat, Dec 27, 2014, 3:37 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

a65232389 5 posts  |  Last Activity: Oct 16, 2014 2:36 PM Member since: Sep 24, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • In the silver-lining press release announcing failure of the trial, "Based on these promising study results and our belief that the beneficial effect of ZADAXIN may extend to vaccines targeting other types of infections and diseases, including cancer, we plan to continue our ongoing dialogue with bio-defense agencies and related groups to determine which vaccines they believe would benefit from enhancement," said Friedhelm Blobel, PhD, SciClone's President and Chief Executive Officer. "While our initial study of ZADAXIN as a vaccine enhancer focused on the H1N1 virus, we believe the product's utility may extend well beyond this initial area of investigation." I guess the 'dialogue' didn't go anywhere. But people get scared and may try anything. Of course, even with no Ebola present in China some doctors might make hay prescribing high priced drugs to the uninformed. Sad way to make money.

  • Reply to

    Offer Zadaxin

    by gonegt Oct 16, 2014 12:26 PM
    a65232389 a65232389 Oct 16, 2014 2:36 PM Flag

    Why not offer it to the appropriate GMO at cost for those at obvious risk in Liberia? Maybe offer to do good rather than just do good PR.

  • Reply to

    Richard Hawkins…50000 shares

    by vodka_voltage Oct 1, 2014 6:30 PM
    a65232389 a65232389 Oct 2, 2014 3:03 PM Flag

    Those options expires in four weeks. After ten years you have to use it or lose it. My guess is he's not allowed to sell but will take a chance at $4.55 purchase price.

  • a65232389 a65232389 Oct 14, 2014 1:08 PM Flag

    Did not reach endpoints. Apparently no interest from anyone, DOD, vaccine companies, pharmaceutical companies, etc. Apparently there is little value in this area.

  • Reply to

    buyout?

    by vodka_voltage Oct 14, 2014 4:30 PM
    a65232389 a65232389 Oct 14, 2014 7:37 PM Flag

    Even better, why not sell the NovaMed subsidiary! It cost SciClone stockholders $100 million in cash. Its goodwill of $35 million still sits on the books, and it generated product and promotion revenue of about $2 million last quarter. SciClone would give it away if they didn't have to finally take the big bath write-down.

SCLN
8.76+0.1200(+1.39%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
PG&E Corporation
NYSEFri, Dec 26, 2014 4:02 PM EST